Clinical Trials

Are you 65 years old or older, and do you have severe primary mitral regurgitation? This condition — also called degenerative mitral regurgitation — happens when there is a problem with the mitral valve itself or its supporting tissue, leading to a leaky valve. This study is comparing the safety and effectiveness of two different ways of repairing the mitral valve: transcatheter edge-to-edge repair and surgical repair. To participate in this study, your healthcare provider must determine that you are a candidate for both mitral valve transcatheter edge-to-edge repair and surgical repair. This study takes place in multiple locations across the United States and Canada.

Do you have cardiomyopathy that has led to moderate or severe mitral regurgitation? This study is exploring the best surgical technique to repair mitral regurgitation by comparing two procedures called undersizing mitral annuloplasty (UMA) and papillary muscle approximation (PMA). A UMA is a common procedure that involves implanting a prosthetic ring onto the mitral valve to stop the valve from leaking. A PMA is a newer technique in which a suture draws together the two muscles that connect the mitral valve to the heart muscle prior to performing UMA. To participate in this study, you must be 18 years old or older and have never had a mitral valve repair procedure. This study takes place in Atlanta, Georgia.

Have you experienced a cardiac event in the past 6 months? This study assesses the efficacy of combining center-based and remote- or home-based cardiac rehabilitation sessions. Many patients who require cardiac rehabilitation, including those with angina myocardial infarction, heart failure, heart valve disease, and coronary heart (artery) disease, do not complete the necessary amount of rehabilitation sessions when done in a center-based environment. Researchers are investigating whether a combination approach will help. To participate in this study, you must be between 18 and 85 years old. This study takes place in Detroit, Michigan.

Are you or your child at least 13 years old and have sickle cell disease? In this stidy, researchers are trying to find out if a new medication improves the success of a blood stem cell transplant. People 13 years old or older who are eligible for a blood stem cell transplant to treat sickle cell disease may be able to participate. Healthy family members over age 13 who are matched to transplant recipients are also needed to donate blood for the study. This study is taking place at the National Institutes of Health Clinical Center in Bethesda, Maryland.